StockNews.com downgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from a buy rating to a hold rating in a research report report published on Wednesday. ACAD has been the topic of several other research reports. Bank of America raised their price target on shares of ACADIA Pharmaceuticals from $26.00 to $29.00 in a research […]